NEW YORK, Feb. 20 - Biosite and Neurocrine Biosciences have signed a three-year research collaboration, the companies said today.
Under the agreement, Neurocrine will provide drug targets, and Biosite will use its phage display technology to generate antibodies to the targets. Biosite will get fees for antibodies when it delivers them to Neurocrine, as well as possible milestone fees, and diagnostic licenses to stroke targets to which Neurocrine has rights. Neurocrine will use the antibodies in its drug discovery research.
Biosite, which focuses on protein-based diagnostics, also has an antibody discovery collaboration agreement with Ciphergen and an agreement to developing protein chips with Large Scale Biology.
For more information on this collaboration, see the company statement.